Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded RNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates.

Atea’s Phase 3 program is evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir an NS5A inhibitor, to treat HCV. The topline results from the HCV program are expected in mid-2026 for the Phase 3 C-BEYOND trial and around the end of 2026 for the Phase 3 C-FORWARD trial. In addition to the HCV program, Atea anticipates initiating clinical development of AT-587, a nucleotide analog, for the treatment of HEV in mid-2026.